Sign In
Buy GENE
$0.765
+0 (+0%)
At Close: Jan 15, 2025
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
10:16am, Monday, 01'st Jun 2026
Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
07:00am, Friday, 29'th May 2026
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
07:00am, Friday, 22'nd May 2026
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessmen
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
02:26pm, Monday, 18'th May 2026
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
M/I HOMES ANNOUNCES ELECTION OF GENE SMITH TO BOARD OF DIRECTORS
02:15pm, Monday, 18'th May 2026
COLUMBUS, Ohio, May 18, 2026 /PRNewswire/ -- M/I Homes, Inc. (NYSE: MHO) today announced that Eugene D. Smith, formerly Senior Vice President and Director of Athletics at The Ohio State University and
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting
BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy
11:50am, Thursday, 23'rd Apr 2026
BridgeBio Pharma, Inc. has surged 130% since last year, now trading at a $14.4bn market cap, driven by optimism around its pipeline and ATTR-CM drug Attruby. Attruby posted $362m in 2025 sales but fac
Genetic variations linked to weight loss, side effects from GLP-1 drugs
04:07pm, Friday, 10'th Apr 2026
Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe.
New 23andMe Research Institute Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects
11:00am, Wednesday, 08'th Apr 2026
PALO ALTO, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for
From Genetic Puzzle to Industrial Platform
09:31am, Wednesday, 08'th Apr 2026
Spider silk's extraordinary combination of strength, elasticity, toughness, biocompatible, biodegradable, and low weight, properties that outperform Kevlar
Agreement Combines Tenaya's Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Mill
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
09:19am, Friday, 27'th Feb 2026
Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinic
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Gene
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026
BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers
07:00am, Tuesday, 24'th Feb 2026
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for Lin
